# Almaprism

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/almaprism

- Industry: Software
- Headquarters: Kyoto-shi, Japan
- Website: www.almaprism.com
- Total disclosed funding: $1M
- Latest round: Seed (Apr 11, 2025)
- Investors on record: 3

## About

Almaprism Inc. is a company focused on developing innovative medical video games that target children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD), utilizing engaging gameplay to enhance cognitive skills and therapeutic outcomes.Almaprism Inc., founded in 2022 in Kyoto-shi, Japan, specializes in creating medical video games aimed at treating ADHD. The company has completed one deal to date, with its most recent funding round being a Seed round on April 11, 2025, where it raised JPY 150 million. The lead investor for this round was SBI Investment, joined by Kyoto Capital Partners and Kyoshin Social Capital. The founder's detailed history is not publicly available, but the company continues to focus on developing its innovative product line from its headquarters in Kyoto-shi.Almaprism Inc. specializes in the development of medical video games aimed primarily at addressing the needs of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Their flagship product utilizes a 3-D video game format to assess and enhance executive functions, providing a novel approach to ADHD treatment. These products are designed to improve cognitive skills through interactive gameplay, making therapy engaging and accessible for younger audiences. Almaprism's offerings are available in multiple geographical markets, including Japan and select international regions, targeting healthcare providers, educational institutions, and families seeking innovative therapeutic solutions for ADHD.The revenue generation model for Almaprism centers around partnerships with healthcare providers and educational institutions, facilitating direct access to their medical video game solutions. Transactions typically occur through subscription agreements or bulk licensing arrangements, allowing schools and clinics to utilize their products over an extended period. Additionally, financial support for product development has been bolstered through grants, such as an AMED Grant specifically for the research and development of new medical devices targeted at ADHD. While specific pricing details are not disclosed, the company’s revenue structure is supported by a combination of direct-to-consumer sales and B2B transactions, enhancing the accessibility and reach of their innovative therapeutic offerings.In April 2025, Almaprism Inc. raised JPY 150 million in Seed funding led by SBI Investment, with participation from Kyoto Capital Partners and Kyoshin Social Capital. This funding will be utilized for clinical studies of its medical software product and for the development of its healthcare app. The company plans to expand its product line with new offerings designed specifically for ADHD treatment, with a targeted rollout in the next 12 months. Additionally, Almaprism aims to penetrate further into international markets, focusing on regions outside Japan by the end of 2026.

## Funding rounds

- Seed, Apr 11, 2025, $1M — SBI Investment, Kyoto Capital Partners, Kyoshin Social Capital

## Investors

- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Seed
- Kyoto Capital Partners (https://capitalatlas.ai/funds/kyoto-capital-partners) — Seed
- Kyoshin Social Capital (https://capitalatlas.ai/funds/kyoshin-social-capital) — Seed